bio investor perception study
TRANSCRIPT
-
8/3/2019 BIO Investor Perception Study
1/16
Welcome to the14th Annual BIO CEO
& Investor Conference
-
8/3/2019 BIO Investor Perception Study
2/16
Alan F. EisenbergExecutive Vice President
Biotechnology Industry Organization (BIO)
-
8/3/2019 BIO Investor Perception Study
3/16
2012 Advisory Committee
Erin Brubaker, VP, WWBD Alliance Management and Head of the AM Centre of Excellence,
GlaxoSmithKline Pharmaceuticals
John Chambers, Managing Director and Head of Healthcare Investment Banking, Roth Capital Partners
Annette Grimaldi, Managing Director, BMO Capital Markets
Michael Hay, Vice President/Product Manager, Sagient Research Systems
Michael G. King, Jr., Managing Director and Senior Biotechnology Analyst, Rodman & Renshaw, LLC
Peter Kolchinksky, PhD, Portfolio Manager, RA Capital Management, LLC
James S.J. Manuso, PhD, MBA, CEO, Astex Pharmaceuticals
Evan McCulloch, Portfolio Manager, Franklin Templeton
Ronald C. Renauld Jr.President and Chief Executive Officer, Idenix Pharmaceuticals
Stephen Sands, Vice Chairman of US Investment Banking and Global Co-Head of Healthcare, Lazard
Mark Schoenebaum, Senior Biotech Analyst, ISI Group
Nathan P. Tinker, PhD, Executive Director, New York Biotechnology Association
-
8/3/2019 BIO Investor Perception Study
4/16
Supporting Bank Sponsors
-
8/3/2019 BIO Investor Perception Study
5/16
-
8/3/2019 BIO Investor Perception Study
6/16
BIO Helix Sponsors
-
8/3/2019 BIO Investor Perception Study
7/16
Conference Sponsors
Local Co-Host
-
8/3/2019 BIO Investor Perception Study
8/16
31 New Drug Approvals In 2011& Several More In 2012
Kalydeco (Vertex) Cystic Fibrosis
Erivedge (Roche/Curis) Basal Cell Carcinoma
Inlyta (Pfizer) Renal Cell Carcinoma
2 Drugs Approved With Companion Diagnostics:
Xalkori (Pfizer) NSCLC
Zelboraf (Daiichi Sankyo/Plexxikon/Roche) MetastaticMelanoma
Adcetris (Seattle Genetics)Lymphoma/Hodgkins
Yervoy (BMS) -- Melanoma
A Comeback For FDA Approvals
2012
-
8/3/2019 BIO Investor Perception Study
9/16
Source: BIO Industry Analysis, FactSet
Median-25%
2011
NBI+11%
Stock Performance Of US Biotechs, 2011
New
issues
since
2007
Acquired orbankrupt since
2007Actively traded since 2007
-
8/3/2019 BIO Investor Perception Study
10/16
Stock Performance Of US Biotechs, YTD
Source: BIO Industry Analysis, FactSet
Median+12%
Average
+29%
2012 YTD (as of Feb 10th)
NBI
+14%
New
issues
since
2007
Acquired orbankrupt since
2007Actively traded since 2007
-
8/3/2019 BIO Investor Perception Study
11/16
Majority Of Investors Still Think It
Is A Good Time To Invest In Biotech
-
8/3/2019 BIO Investor Perception Study
12/16
Investors More Focused On Early Stage,
Taking Greater Risk On Less Liquid Cos
-
8/3/2019 BIO Investor Perception Study
13/16
Autoimmune & Oncology Seen As The
Most Attractive Areas To Invest
-
8/3/2019 BIO Investor Perception Study
14/16
Investors Expect MORE
Biotech IPOs In 2012
23
13
17
12
0
5
10
15
20
25
2007 2008 2009 2010 2011
#IPOs
US IPOs
-
8/3/2019 BIO Investor Perception Study
15/16
This presentation may contain forward-lookingstatements. Actual results may differ materially from
such forward-looking statements as a result of various
factors involving uncertainties and risks that vary from
company to company. The specific uncertainties andrisks pertaining to individual publicly-traded companies
at this conference should be reviewed in each
companys Form 10-K report and other such documents
filed with the Securities and Exchange Commission.
Some companies may be clients of the Conference
sponsors or members of BIO.
-
8/3/2019 BIO Investor Perception Study
16/16
Opening Plenary:
Picks and Pans The Buy-Side View for 2012
Moderator:
Stephen Sands - Vice Chairman of US Investment Banking and Global Co-Headof Healthcare, Lazard
Panelists:
Alexander J. Denner, PhD - (former) Managing Director, Icahn Associates
Rajiv Kaul - Portfolio Manager Fidelity Select Biotechnology Portfolio, Fidelity
Greg Martinez - Portfolio Manager, Diamondback Capital Management LLC
Deepa R. Pakianathan, PhD - General Partner, Delphi Ventures